Schond Greenway
2021 - Avalo Therapeutics
In 2021, Schond Greenway earned a total compensation of $1.7M as Former Chief Financial Officer and former principal financial officer at Avalo Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $141,708 |
|---|---|
| Option Awards | $1,241,608 |
| Salary | $293,269 |
| Total | $1,676,585 |
Greenway received $1.2M in option awards, accounting for 74% of the total pay in 2021.
Greenway also received $141.7K in non-equity incentive plan and $293.3K in salary.
Rankings
In 2021, Schond Greenway's compensation ranked 6,763rd out of 12,415 executives tracked by ExecPay. In other words, Greenway earned more than 45.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,763 out of 12,415 | 46th |
Division Manufacturing | 2,936 out of 5,505 | 47th |
Major group Chemicals And Allied Products | 1,296 out of 2,375 | 45th |
Industry group Drugs | 1,155 out of 2,096 | 45th |
Industry Pharmaceutical Preparations | 843 out of 1,546 | 46th |
Source: SEC filing on April 25, 2022.
Greenway's colleagues
We found four more compensation records of executives who worked with Schond Greenway at Avalo Therapeutics in 2021.